<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><description>医药行业一致性评价工作在如火如荼的进行中，作为行业的一份子，愿本愚公之念，出蝼蚁 之力，献寸光之策。</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 16 Mar 2021 23:26:02 +0800</pubDate><image><url>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</url><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>（2021.3.16）最新过评名单，4品种决出首家！</title><link>https://mp.weixin.qq.com/s/lBmZVSdszCyIp0vE6DXDLw</link><description></description><content:encoded><![CDATA[（2021.3.16）最新过评名单，4品种决出首家！]]></content:encoded><pubDate>Tue, 16 Mar 2021 21:40:22 +0800</pubDate></item><item><title>“小身材、大潜力”-厄他培南，3亿国内市场在持续迸发...</title><link>https://mp.weixin.qq.com/s/YzuzHrCdb4OQfeecUsdSyQ</link><description></description><content:encoded><![CDATA[“小身材、大潜力”-厄他培南，3亿国内市场在持续迸发...]]></content:encoded><pubDate>Tue, 16 Mar 2021 21:40:22 +0800</pubDate></item><item><title>CDE：皮肤外用仿制药，有了新技术指导原则！</title><link>https://mp.weixin.qq.com/s/YHERuz7ryOniFvF9yh0ZoQ</link><description></description><content:encoded><![CDATA[CDE：皮肤外用仿制药，有了新技术指导原则！]]></content:encoded><pubDate>Tue, 16 Mar 2021 21:40:22 +0800</pubDate></item><item><title>佰药云—注册代理服务</title><link>https://mp.weixin.qq.com/s/mjv12h4d91T5hl8JHnWopQ</link><description></description><content:encoded><![CDATA[佰药云—注册代理服务]]></content:encoded><pubDate>Tue, 16 Mar 2021 21:40:22 +0800</pubDate></item><item><title>17个品种！第二批鼓励仿制药目录发布</title><link>https://mp.weixin.qq.com/s/lmEOJNsxXdiUzkEVF0lF-A</link><description></description><content:encoded><![CDATA[17个品种！第二批鼓励仿制药目录发布]]></content:encoded><pubDate>Tue, 16 Mar 2021 21:40:22 +0800</pubDate></item><item><title>2月一致性评价：申报量回落，17品种首家过评…</title><link>https://mp.weixin.qq.com/s/zC2C7Oas0JEjhsgxcKwZpQ</link><description></description><content:encoded><![CDATA[2月一致性评价：申报量回落，17品种首家过评…]]></content:encoded><pubDate>Mon, 15 Mar 2021 21:41:32 +0800</pubDate></item><item><title>二甲双胍再现新功效</title><link>https://mp.weixin.qq.com/s/TcoNSrk29K7NzZx56p5izQ</link><description></description><content:encoded><![CDATA[二甲双胍再现新功效]]></content:encoded><pubDate>Mon, 15 Mar 2021 21:41:32 +0800</pubDate></item><item><title>关于新版基药目录调整，看看人大代表怎么说？</title><link>https://mp.weixin.qq.com/s/blvJASt4oPdNxZa408MdCQ</link><description></description><content:encoded><![CDATA[关于新版基药目录调整，看看人大代表怎么说？]]></content:encoded><pubDate>Mon, 15 Mar 2021 21:41:32 +0800</pubDate></item><item><title>佰药云—找产品服务</title><link>https://mp.weixin.qq.com/s/lW_Kj81MhfVKhAURfYuzGw</link><description></description><content:encoded><![CDATA[佰药云—找产品服务]]></content:encoded><pubDate>Mon, 15 Mar 2021 21:41:32 +0800</pubDate></item><item><title>CDE发布：化学创新药临床药学变更指导原则</title><link>https://mp.weixin.qq.com/s/CDf61lYh5od5nCwBsbFaMg</link><description></description><content:encoded><![CDATA[CDE发布：化学创新药临床药学变更指导原则]]></content:encoded><pubDate>Mon, 15 Mar 2021 21:41:32 +0800</pubDate></item><item><title>全球最大的多肽类供应商之一，和它的王牌品种！</title><link>https://mp.weixin.qq.com/s/6mrG-dk95Gz8q318WuO_Jg</link><description></description><content:encoded><![CDATA[全球最大的多肽类供应商之一，和它的王牌品种！]]></content:encoded><pubDate>Sun, 14 Mar 2021 22:28:23 +0800</pubDate></item><item><title>引进日本产品，它能帮你！</title><link>https://mp.weixin.qq.com/s/kzLM-LvzNdnKe8Odk2fFtg</link><description></description><content:encoded><![CDATA[引进日本产品，它能帮你！]]></content:encoded><pubDate>Sun, 14 Mar 2021 22:28:23 +0800</pubDate></item><item><title>佰药云—产品推广服务</title><link>https://mp.weixin.qq.com/s/YbUsosi_tzUxWyRiI81dFA</link><description></description><content:encoded><![CDATA[佰药云—产品推广服务]]></content:encoded><pubDate>Sun, 14 Mar 2021 22:28:23 +0800</pubDate></item><item><title>当原料药与制剂，不得不分手时……</title><link>https://mp.weixin.qq.com/s/3WdxdGiR-voFTzS883m-CA</link><description></description><content:encoded><![CDATA[当原料药与制剂，不得不分手时……]]></content:encoded><pubDate>Fri, 12 Mar 2021 18:39:19 +0800</pubDate></item><item><title>【项目合作】三款进口大健康产品，寻国内经销商</title><link>https://mp.weixin.qq.com/s/e25ALYBNDWdF-WuNK6ctnQ</link><description></description><content:encoded><![CDATA[【项目合作】三款进口大健康产品，寻国内经销商]]></content:encoded><pubDate>Fri, 12 Mar 2021 18:39:19 +0800</pubDate></item><item><title>3品种首家过评，涉及一品红、石药、华润等大药企！</title><link>https://mp.weixin.qq.com/s/zKOvrCeWU5Kk6NfRYz2k9A</link><description></description><content:encoded><![CDATA[3品种首家过评，涉及一品红、石药、华润等大药企！]]></content:encoded><pubDate>Fri, 12 Mar 2021 21:38:30 +0800</pubDate></item><item><title>刚刚！第四十一批参比目录公示，13个品种审议不通过...</title><link>https://mp.weixin.qq.com/s/sKkhxrsI2RonW1k1EDIpXA</link><description></description><content:encoded><![CDATA[刚刚！第四十一批参比目录公示，13个品种审议不通过...]]></content:encoded><pubDate>Fri, 12 Mar 2021 21:38:30 +0800</pubDate></item><item><title>注意！这6个药品被撤网</title><link>https://mp.weixin.qq.com/s/-5TVp7aPueOQQLW3YE4GVA</link><description></description><content:encoded><![CDATA[注意！这6个药品被撤网]]></content:encoded><pubDate>Fri, 12 Mar 2021 21:38:30 +0800</pubDate></item><item><title>集采后产物，大批药品联动降价</title><link>https://mp.weixin.qq.com/s/9yRR6Clf-kWaegvmcr66mg</link><description></description><content:encoded><![CDATA[集采后产物，大批药品联动降价]]></content:encoded><pubDate>Fri, 12 Mar 2021 21:38:30 +0800</pubDate></item><item><title>佰药云—调研报告服务</title><link>https://mp.weixin.qq.com/s/pYGWy9Yp7Exkeey4Bw804w</link><description></description><content:encoded><![CDATA[佰药云—调研报告服务]]></content:encoded><pubDate>Fri, 12 Mar 2021 21:38:30 +0800</pubDate></item></channel></rss>